
Last updated: 2026-09-08 22:19:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Alector, Inc. (ALEC) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.47, with a market capitalization of $274.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.09 to $3.40. This page covers its latest market performance, valuation, price trends and company information.
$274.68M | |
$2.38 | |
$43.32 | |
$0.87 | |
$2.46 | |
857.13K | |
1.02M | |
-- | |
$3.40 | |
$1.09 | |
-- | |
-- |
Alector, Inc. (ALEC) is trading at $2.48 in after-hours trading as of 2026-09-08 21:37:00, up 0.61% ($0.02) from the regular-session close of $2.46.
After-hours trading shows how investors are pricing ALEC after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Alector, Inc. (ALEC) moved from $2.39 to $2.47, representing a gain of 3.39% ($0.08).
The stock traded between $2.22 and $2.76 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1.04 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 59.8%
ALEC is currently trading at $2.47, placing it 59.8% of the way from its 52-week low of $1.09 to its 52-week high of $3.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 103 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alector, Inc. (ALEC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.